vs

Side-by-side financial comparison of Orchestra BioMed Holdings, Inc. (OBIO) and TELEFLEX INC (TFX). Click either name above to swap in a different company.

TELEFLEX INC runs the higher net margin — 177.8% vs 20.2%, a 157.6% gap on every dollar of revenue. On growth, Orchestra BioMed Holdings, Inc. posted the faster year-over-year revenue change (12120.2% vs -150.5%). Orchestra BioMed Holdings, Inc. produced more free cash flow last quarter ($-2.3M vs $-92.9M). Over the past eight quarters, TELEFLEX INC's revenue compounded faster (NaN% CAGR vs NaN%).

Orchestra BioMed Holdings, Inc. is a clinical-stage medical technology company focused on developing novel, evidence-based therapeutic solutions for cardiovascular and other high-burden chronic diseases. It collaborates with leading healthcare stakeholders, operates primarily across North American and European markets, with core segments covering interventional cardiology and chronic disease care optimization.

Teleflex Incorporated, headquartered in Wayne, Pennsylvania, is an American provider of specialty medical devices for a range of procedures in critical care and surgery. Teleflex has annual revenues of $2.4 billion, operations in 40 countries, and more than 15,000 employees. By 2011, the company had substantially realigned to focus on its current business as a medical-device manufacturer, having undergone several years of active acquisitions and divestitures. Teleflex has been associated with...

OBIO vs TFX — Head-to-Head

Bigger by revenue
OBIO
OBIO
-0.1× larger
OBIO
$30.9M
$-401.9M
TFX
Growing faster (revenue YoY)
OBIO
OBIO
+12270.7% gap
OBIO
12120.2%
-150.5%
TFX
Higher net margin
TFX
TFX
157.6% more per $
TFX
177.8%
20.2%
OBIO
More free cash flow
OBIO
OBIO
$90.6M more FCF
OBIO
$-2.3M
$-92.9M
TFX
Faster 2-yr revenue CAGR
TFX
TFX
Annualised
TFX
NaN%
606.2%
OBIO

Income Statement — Q4 2025 vs Q4 2025

Metric
OBIO
OBIO
TFX
TFX
Revenue
$30.9M
$-401.9M
Net Profit
$6.2M
$-714.3M
Gross Margin
99.8%
Operating Margin
21.8%
Net Margin
20.2%
177.8%
Revenue YoY
12120.2%
-150.5%
Net Profit YoY
138.7%
-422.7%
EPS (diluted)
$0.28
$-15.85

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OBIO
OBIO
TFX
TFX
Q4 25
$30.9M
$-401.9M
Q3 25
$861.0K
$913.0M
Q2 25
$836.0K
$780.9M
Q1 25
$868.0K
$700.7M
Q4 24
$253.0K
$795.4M
Q3 24
$987.0K
$764.4M
Q2 24
$778.0K
$749.7M
Q1 24
$620.0K
$737.8M
Net Profit
OBIO
OBIO
TFX
TFX
Q4 25
$6.2M
$-714.3M
Q3 25
$-20.8M
$-408.9M
Q2 25
$-19.4M
$122.6M
Q1 25
$-18.8M
$95.0M
Q4 24
$-16.2M
$-136.7M
Q3 24
$-15.4M
$111.0M
Q2 24
$-16.0M
$80.0M
Q1 24
$-13.5M
$15.3M
Gross Margin
OBIO
OBIO
TFX
TFX
Q4 25
99.8%
Q3 25
94.3%
49.5%
Q2 25
94.5%
55.2%
Q1 25
94.9%
55.6%
Q4 24
77.1%
55.3%
Q3 24
93.1%
56.3%
Q2 24
94.3%
55.6%
Q1 24
94.5%
56.4%
Operating Margin
OBIO
OBIO
TFX
TFX
Q4 25
21.8%
Q3 25
-2359.2%
-44.8%
Q2 25
-2311.8%
19.9%
Q1 25
-2179.8%
17.9%
Q4 24
-6591.7%
-13.9%
Q3 24
-1655.7%
19.5%
Q2 24
-2167.0%
15.6%
Q1 24
-2326.3%
-0.6%
Net Margin
OBIO
OBIO
TFX
TFX
Q4 25
20.2%
177.8%
Q3 25
-2419.0%
-44.8%
Q2 25
-2316.1%
15.7%
Q1 25
-2160.7%
13.6%
Q4 24
-6385.4%
-17.2%
Q3 24
-1562.9%
14.5%
Q2 24
-2054.0%
10.7%
Q1 24
-2171.5%
2.1%
EPS (diluted)
OBIO
OBIO
TFX
TFX
Q4 25
$0.28
$-15.85
Q3 25
$-0.40
$-9.24
Q2 25
$-0.50
$2.77
Q1 25
$-0.49
$2.07
Q4 24
$-0.42
$-2.89
Q3 24
$-0.41
$2.36
Q2 24
$-0.45
$1.69
Q1 24
$-0.38
$0.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OBIO
OBIO
TFX
TFX
Cash + ST InvestmentsLiquidity on hand
$106.5M
$378.6M
Total DebtLower is stronger
$15.0M
$2.6B
Stockholders' EquityBook value
$53.6M
$3.1B
Total Assets
$114.9M
$6.9B
Debt / EquityLower = less leverage
0.28×
0.85×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OBIO
OBIO
TFX
TFX
Q4 25
$106.5M
$378.6M
Q3 25
$95.8M
$354.0M
Q2 25
$33.9M
$253.7M
Q1 25
$49.9M
$284.1M
Q4 24
$66.8M
$290.2M
Q3 24
$66.9M
$243.2M
Q2 24
$65.2M
$238.6M
Q1 24
$75.0M
$237.4M
Total Debt
OBIO
OBIO
TFX
TFX
Q4 25
$15.0M
$2.6B
Q3 25
$15.0M
$2.7B
Q2 25
$15.0M
$1.9B
Q1 25
$15.0M
$1.9B
Q4 24
$15.0M
$1.7B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
OBIO
OBIO
TFX
TFX
Q4 25
$53.6M
$3.1B
Q3 25
$43.7M
$3.8B
Q2 25
$295.0K
$4.2B
Q1 25
$16.9M
$4.1B
Q4 24
$33.0M
$4.3B
Q3 24
$46.2M
$4.5B
Q2 24
$44.1M
$4.6B
Q1 24
$57.2M
$4.5B
Total Assets
OBIO
OBIO
TFX
TFX
Q4 25
$114.9M
$6.9B
Q3 25
$104.8M
$7.9B
Q2 25
$42.8M
$7.4B
Q1 25
$59.1M
$7.2B
Q4 24
$76.2M
$7.1B
Q3 24
$75.3M
$7.5B
Q2 24
$72.4M
$7.4B
Q1 24
$82.6M
$7.5B
Debt / Equity
OBIO
OBIO
TFX
TFX
Q4 25
0.28×
0.85×
Q3 25
0.34×
0.70×
Q2 25
50.85×
0.45×
Q1 25
0.89×
0.47×
Q4 24
0.46×
0.39×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OBIO
OBIO
TFX
TFX
Operating Cash FlowLast quarter
$-2.3M
$-92.3M
Free Cash FlowOCF − Capex
$-2.3M
$-92.9M
FCF MarginFCF / Revenue
-7.4%
23.1%
Capex IntensityCapex / Revenue
0.1%
-0.2%
Cash ConversionOCF / Net Profit
-0.36×
TTM Free Cash FlowTrailing 4 quarters
$-49.5M
$1.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OBIO
OBIO
TFX
TFX
Q4 25
$-2.3M
$-92.3M
Q3 25
$-14.6M
$107.8M
Q2 25
$-15.5M
$7.8M
Q1 25
$-16.6M
$73.3M
Q4 24
$-13.5M
$202.6M
Q3 24
$-13.7M
$231.1M
Q2 24
$-10.2M
$91.7M
Q1 24
$-13.1M
$112.8M
Free Cash Flow
OBIO
OBIO
TFX
TFX
Q4 25
$-2.3M
$-92.9M
Q3 25
$-14.9M
$77.8M
Q2 25
$-15.6M
$-26.8M
Q1 25
$-16.7M
$43.3M
Q4 24
$-13.6M
$170.6M
Q3 24
$-13.8M
$209.9M
Q2 24
$-10.3M
$56.9M
Q1 24
$-13.1M
$74.4M
FCF Margin
OBIO
OBIO
TFX
TFX
Q4 25
-7.4%
23.1%
Q3 25
-1725.9%
8.5%
Q2 25
-1861.4%
-3.4%
Q1 25
-1927.2%
6.2%
Q4 24
-5392.9%
21.4%
Q3 24
-1394.9%
27.5%
Q2 24
-1325.6%
7.6%
Q1 24
-2116.5%
10.1%
Capex Intensity
OBIO
OBIO
TFX
TFX
Q4 25
0.1%
-0.2%
Q3 25
36.0%
3.3%
Q2 25
4.1%
4.4%
Q1 25
12.9%
4.3%
Q4 24
41.9%
4.0%
Q3 24
6.9%
2.8%
Q2 24
13.8%
4.6%
Q1 24
1.3%
5.2%
Cash Conversion
OBIO
OBIO
TFX
TFX
Q4 25
-0.36×
Q3 25
Q2 25
0.06×
Q1 25
0.77×
Q4 24
Q3 24
2.08×
Q2 24
1.15×
Q1 24
7.38×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons